Alector 미래 성장
Future 기준 확인 2/6
Alector is forecast to grow earnings and revenue by 61.1% and 57.5% per annum respectively. EPS is expected to grow by 60.9% per annum. Return on equity is forecast to be -75.3% in 3 years.
주요 정보
61.1%
수익 성장률
60.9%
EPS 성장률
| Biotechs 수익 성장 | 27.1% |
| 매출 성장률 | 57.5% |
| 향후 자기자본 수익률 | -75.3% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 19 Sep 2024 |
최근 미래 성장 업데이트
Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11
Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01Recent updates
Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry
Oct 24We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully
Sep 26Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking
Jul 11Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results
Mar 01The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%
Jan 19Alector: Good Data, Huge Cash, No Near Term Catalyst
Jan 16Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Sep 25Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation
Jun 27Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week
Mar 02Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
Jan 16Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential
Oct 04AbbVie ends partnership with Alector for Alzheimer’s candidate
Jul 08Alector: Potential In Neurology And Cancer Treatments
Jun 14Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022
May 18Alector: Expect Phase 3 Data Next Year
Apr 16These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts
Feb 27Alector, Inc: A Newer Biotech Company With Big Potential
Jan 26Alector: The GSK Deal Is A Major Value Add
Oct 29수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 107 | -193 | -227 | -142 | 5 |
| 12/31/2025 | 127 | -113 | -139 | -24 | 9 |
| 12/31/2024 | 63 | -183 | -147 | -179 | 10 |
| 6/30/2024 | 55 | -161 | -218 | -217 | N/A |
| 3/31/2024 | 96 | -121 | -199 | -197 | N/A |
| 12/31/2023 | 97 | -130 | -187 | -184 | N/A |
| 9/30/2023 | 96 | -141 | -190 | -187 | N/A |
| 6/30/2023 | 102 | -143 | -194 | -190 | N/A |
| 3/31/2023 | 126 | -135 | -208 | -204 | N/A |
| 12/31/2022 | 134 | -133 | -24 | -20 | N/A |
| 9/30/2022 | 133 | -136 | -25 | -21 | N/A |
| 6/30/2022 | 301 | 36 | 471 | 473 | N/A |
| 3/31/2022 | 227 | -29 | 483 | 486 | N/A |
| 12/31/2021 | 207 | -36 | 295 | 299 | N/A |
| 9/30/2021 | 198 | -33 | 297 | 300 | N/A |
| 6/30/2021 | 21 | -212 | -189 | -186 | N/A |
| 3/31/2021 | 18 | -202 | -190 | -187 | N/A |
| 12/31/2020 | 21 | -190 | -172 | -167 | N/A |
| 9/30/2020 | 22 | -169 | -154 | -148 | N/A |
| 6/30/2020 | 19 | -148 | -144 | -136 | N/A |
| 3/31/2020 | 23 | -127 | -125 | -108 | N/A |
| 12/31/2019 | 21 | -105 | -115 | -99 | N/A |
| 9/30/2019 | 24 | -92 | -102 | -88 | N/A |
| 6/30/2019 | 28 | -76 | -94 | -82 | N/A |
| 3/31/2019 | 28 | -62 | -84 | -81 | N/A |
| 12/31/2018 | 28 | -52 | 126 | 127 | N/A |
| 9/30/2018 | 22 | -45 | 141 | 143 | N/A |
| 6/30/2018 | 15 | -39 | 157 | 159 | N/A |
| 3/31/2018 | 8 | -35 | N/A | 171 | N/A |
| 12/31/2017 | 4 | -32 | N/A | -18 | N/A |
| 12/31/2016 | 0 | -15 | N/A | -13 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: ALEC is forecast to remain unprofitable over the next 3 years.
수익 vs 시장: ALEC is forecast to remain unprofitable over the next 3 years.
고성장 수익: ALEC is forecast to remain unprofitable over the next 3 years.
수익 대 시장: ALEC's revenue (57.5% per year) is forecast to grow faster than the US market (8.9% per year).
고성장 수익: ALEC's revenue (57.5% per year) is forecast to grow faster than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: ALEC is forecast to be unprofitable in 3 years.